Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments

Why did the Federal Reserve renovation cost escalate? How will the US-Japan tariff deal affect automakers? What caused Tesla’s recent profit decline? Why is UnitedHealth under federal investigation? How did the Paramount-Skydance merger get FCC approval? What impact will Trump’s AI action plan have? Why are HydroTech hoses being recalled nationwide?

Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments

marketwatch.com/story/sarepta-therapeutics-stock-slips-further-as-company-bows-to-fda-pressure-to-halt-shipments-03a634b2

Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.

This story appeared on marketwatch.com, 2025-07-22 10:44:00.